Acrivon Therapeutics, Inc. announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president and head, investor relations and corporate affairs. Previously, Adam served as senior vice president of investor relations at Zentalis Pharmaceuticals. Prior to Zentalis, he was senior vice president of investor relations and corporate communications at Turning Point Therapeutics, where he was part of the team that delivered a $4.1 billion transaction when the company was acquired by Bristol Myers Squibb in 2022.

Earlier in his career he held positions of increasing responsibility in corporate strategy and corporate development at Pfizer, Novartis AG, Alexion Pharmaceuticals, and Gilead Sciences, where he was the head of corporate strategy, leading the delivery of the first long-term strategic plan for the $100 billion market cap enterprise. Adam has also served as an engagement manager at McKinsey and Company, focusing on supporting clients in the pharmaceutical industry to identify long-term growth strategies and opportunities. Adam received an M.B.A. from the Kellogg School of Management at Northwestern University, a Ph.D. in Molecular Biology from the University of Illinois at Chicago, and a B.S. in Genetics from the University of Illinois at Urbana-Champaign.